These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Rocuronium-sugammadex for electroconvulsive therapy management in neuroleptic malignant syndrome: A case report.
    Author: Casas Reza P, Gestal Vázquez M, Outeiro Rosato Á, López Álvarez S, Diéguez García P.
    Journal: Rev Esp Anestesiol Reanim; 2017 Feb; 64(2):105-107. PubMed ID: 27424873.
    Abstract:
    Neuroleptics are a group of drugs widely used in the treatment of psychotic symptoms. Among their adverse effects is the ability to trigger a neuroleptic malignant syndrome (NMS). The diagnosis of NMS is determined by exclusion, and its initial therapeutic management should be the withdrawal of neuroleptics, the administration of benzodiazepines, and electroconvulsive therapy (ECT). ECT is an effective treatment in these patients, and in those cases with a poor response to treatment with antipsychotic drugs. A review is presented on the treatment options and anaesthetic implications of ECT used to handle a patient diagnosed with paranoid schizophrenia in the context of NMS.
    [Abstract] [Full Text] [Related] [New Search]